Contact UsCOVID-19 Vaccine Tracker
-
Phase 1
Vaccines in small-scale safety trials
50
-
Phase 2
Vaccines in expanded safety trials
51
-
Phase 3
Vaccines in large-scale efficacy trials
45
-
Phase 4
Vaccines Approved for Other Indications/COVID-19
4
-
Approved
Emergency Approval / Limited Use
40
-
Terminated
Trials which are discontinued by the sponsors
10
-
Paused
Trials which are paused by the sponsors
0
Choose | Sr. No. | Phase of Trial | Country | Condition | Product Name | Intervention | Vaccine Type | MOA/Technology | Sponsor/Collaborators | COMPLETION DATE | LAUNCH YEAR | TRIAL NUMBER | TRIAL NAME |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APPROVED (PHASE 2) IRAN | AUSTRALIA | SARS-COV2 (COVID-19) | COVAX-19 | SPIKOGEN | COVID19 VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | VAXINE PTY LTD | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED | 01-07-2020 | Q1 2021 | NCT04453852 | COVAX-19 |
| 2 | APPROVED (ARGENTINA, EUROPE, CANADA)-VACCINE SUSPENDED IN FRANCE,GERMANY AND ITALY | BRAZIL | SARS-COV2 (COVID-19) | ChAdOx1 nCoV-19 | CHADOX1-S | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY OF OXFORD | ASTRAZENECA | 31-10-2021 | Q4 2020 | ISRCTN89951424 | - |
| 3 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | CORONAVAC | INACTIVATED SARS-COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SINOVAC | 28-08-2020 | Q1 2021 | NCT04383574 | - |
| 4 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | CORONAVAC | INACTIVATED SARS-COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SINOVAC | 10-07-2020 | Q1 2021 | NCT04352608 | - |
| 5 | APPROVED (CHINA), EMERGENCY USE (MEXICO, PAKISTAN) | CHINA | SARS-COV2 (COVID-19) | CONVIDECIA | RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CANSINO BIOLOGICS INC. | BEIJING INSTITUTE OF BIOTECHNOLOGY | 30-12-2021 | Q2 2022 | NCT04526990 | - |
| 6 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED NOVEL CORONAVIRUS PNEUMONIA VACCINE (VERO CELLS) | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS | SINOPHARM | 11-10-2021 | Q1 2021 | CHICTR2000031809 | - |
| 7 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT NEW CORONAVIRUS VACCINE (CHO CELL) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | ANHUI ZHIFEI LONGCOM BIOLOGIC PHARMACY CO., LTD. | 15-09-2021 | Q1 2022 | NCT04466085 | - |
| 8 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | - | NEW CORONAVIRUS VACCINE (CHO CELL) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | ANHUI ZHIFEI LONGCOM BIOLOGIC PHARMACY CO., LTD. | 01-04-2022 | Q4 2022 | NCT04646590 | - |
| 9 | APPROVED (CHINA) | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE (VERO CELLS) | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD | 30-06-2021 | Q1 2022 | NCT04756323 | - |
| 10 | APPROVED (UAE, BAHRAIN, CHINA,HUNGARY) | CHINA | SARS-COV2 (COVID-19) | BBIBP-CorV | INACTIVATED NOVEL CORONAVIRUS (2019-COV) VACCINE (VERO CELLS) | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS | SINOPHARM | 28-11-2021 | Q4 2020 | CHICTR2000032459 | - |
| 11 | APPROVED FOR EMERGENCY USE (PHASE 3) IRAN, CUBA | CUBA | SARS-COV2 (COVID-19) | SOBERANA 2 | CORONAVIRUS SPIKE PROTEIN FUSED WITH TETANUS VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | FINLAY VACCINE INSTITUTE | - | Q4 2022 | RPCEC00000354-Sp | - |
| 12 | APPROVED FOR EMERGENCY USE (PHASE 3) | CUBA | SARS-COV2 (COVID-19) | ABDALA | CIGB-66 | RNA VACCINE | A PROTEIN FRAGMENT | CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (CIGB) | - | Q3 2022 | IG/CIGB-66I/CVD19/2002 | - |
| 13 | APPROVED FOR EMERGENCY USE (PHASE 3) CUBA | CUBA | SARS-COV2 (COVID-19) | SOBERANA PLUS | RBD SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | FINLAY VACCINE INSTITUTE | 11-01-2021 | Q2 2021 | RPCEC00000366 | - |
| 14 | APPROVED (EUROPE) | GERMANY | SARS-COV2 (COVID-19) | COMIRNATY | BNT162A1, BNT162B1, BNT162B2, BNT162C2 | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH SE | 01-11-2020 | Q4 2020 | NCT04380701 | - |
| 15 | APPROVED (UK) | GERMANY | SARS-COV2 (COVID-19) | COMIRNATY | 3 LNP-MRNAS | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH | FOSUN PHARMA |PFIZER | 01-10-2020 | Q4 2020 | 2020-001038-36 | - |
| 16 | APPROVED (INDIA) | INDIA | SARS-COV2 (COVID-19) | COVAXIN | INACTIVATED VIRUS WHOLE-VIRION INACTIVATED (COVAXIN) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | BHARAT BIOTECH ; NATIONAL INSTITUTE OF VIROLOGY | NA | Q4 2020 | CTRI/2020/07/026300 | - |
| 17 | APPROVED (INDIA) | INDIA | SARS-COV2 (COVID-19) | BBV152 | BBV152 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | BHARAT BIOTECH INTERNATIONAL LIMITED|INDIAN COUNCIL OF MEDICAL RESEARCH|IQVIA PTY LTD | 30-06-2021 | Q4 2020 | NCT04641481 | - |
| 18 | APPROVED (INDIA) | INDIA | SARS-COV2 (COVID-19) | BBV152 | BBV152A, BBV152B, BBV152C | RNA VACCINE | A PROTEIN FRAGMENT | BHARAT BIOTECH INTERNATIONAL LIMITED | INDIAN COUNCIL OF MEDICAL RESEARCH | 30-06-2021 | Q4 2020 | NCT04471519 | BBV152 |
| 19 | APPROVED (INDIA) | INDIA | SARS-COV2 (COVID-19) | ZYCOV-D | DNA-BASED DNA PLASMID (ZYCOV-D) | RNA VACCINE | A PROTEIN FRAGMENT | ZYDUS CADILA HEALTHCARE LIMITED | NA | Q2 2021 | CTRI/2020/07/026352 | - |
| 20 | APPROVED FOR EMERGENCY USE (PHASE 3) | IRAN | SARS-COV2 (COVID-19) | COVIran Barekat | INACTIVATED CORONAVIRUS | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SHAFA PHARMED PARS | NA | Q2 2021 | - | - |
| 21 | APPROVED (KAZAKHSTAN) | KAZAKHSTAN | SARS-COV2 (COVID-19) | QazVac | QazCovid-in | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS | NATIONAL SCIENTIFIC CENTER FOR PHTHISIOPULMONOLOGY OF THE REPUBLIC OF KAZAKHSTAN | 31-12-2020 | Q1 2021 | NCT04530357 | - |
| 22 | APPROVED (RUSSIA, INDIA) | RUSSIA | SARS-COV2 (COVID-19) | SPUTNIK V | Gam-COVID-Vac | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | GAMALEYA RESEARCH INSTITUTE | 03-08-2020 | Q2 2020 | NCT04436471 | - |
| 23 | APPROVED (RUSSIA) | RUSSIA | SARS-COV2 (COVID-19) | SPUTNIK LIGHT (SINGLE DOSE VACCINE) | Gam-COVID-Vac | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | GAMALEYA RESEARCH INSTITUTE | 16-11-2021 | Q1 2022 | NCT04684446 | - |
| 24 | APPROVED FOR EMERGENCY USE (PHASE 2) TAIWAN | TAIWAN | SARS-COV2 (COVID-19) | MVC-COV1901 | MVC-COV1901 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | MEDIGEN VACCINE BIOLOGICS CORP. | 30-05-2021 | Q4 2021 | NCT04487210 | - |
| 25 | APPROVED (CHINA) | UAE | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE (VERO CELL) | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS | SINOPHARM | 15-07-2021 | Q3 2020 | ChiCTR2000034780 | - |
| 26 | APPROVED (EUROPE, INDIA, SOUTH AFRICA)-VACCINE SUSPENDED IN FRANCE,GERMANY AND ITALY | UNITED KINGDOM | SARS-COV2 (COVID-19) | AZD1222, ChAdOx1 nCoV-19, COVISHIELD | CHADOX1 NCOV-19,MENACWY | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | THE UNIVERSITY OF OXFORD |'ASTRAZENECA | IQVIA | SERUM INSTITUTE OF INDIA | 01-05-2021 | Q4 2020 | NCT04324606 | - |
| 27 | APPROVED (EUROPE, SOUTH AFRICA)-VACCINE SUSPENDED IN FRANCE,GERMANY AND ITALY | UNITED KINGDOM | SARS-COV2 (COVID-19) | AZD1222, ChAdOx1 nCoV-19 | CHADOX1-S | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY OF OXFORD | ASTRAZENECA | 01-08-2021 | Q4 2020 | 2020-001228-32 | - |
| 28 | APPROVED (EUROPE, SOUTH AFRICA)-VACCINE SUSPENDED IN FRANCE,GERMANY AND ITALY | UNITED KINGDOM | SARS-COV2 (COVID-19) | AZD1222, ChAdOx1 nCoV-19 | CHADOX1-S | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY OF OXFORD | ASTRAZENECA | 01-05-2021 | Q4 2020 | PACTR202006922165132, 2020-001072-15 | - |
| 29 | APPROVED (UK) | UNITED KINGDOM | SARS-COV2 (COVID-19) | AZD1222, ChAdOx1 nCoV-19 | CHADOX1 NCOV-19 (ABS 260), MENACWY VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY OF OXFORD | 01-08-2021 | Q4 2020 | NCT04400838 | - |
| 30 | APPROVED (UK) | UNITED KINGDOM | SARS-COV2 (COVID-19) | VLA2001 | VERO-CELL BASED INACTIVATED VIRUS | RNA VACCINE | A PROTEIN FRAGMENT | VALNEVA | 16-12-2020 | Q2 2021 | NA | - |
| 31 | APPROVED (INDIA) | USA | SARS-COV2 (COVID-19) | CORBEVAX | BCG VACCINE | REPURPOSED VACCINES | MULTIDISEASE/MULTIPATHOGEN VECTOR VACCINE | TEXAS A&M UNIVERSITY | BAYLOR COLLEGE OF MEDICINE | M.D. ANDERSON CANCER CENTER | CEDARS-SINAI MEDICAL CENTER | HARVARD UNIVERSITY | 01-05-2021 | Q4 2021 | NCT04348370 | BADAS |
| 32 | APPROVED | USA | SARS-COV2 (COVID-19) | COMIRNATY | BNT162A1, BNT162B1, BNT162B2, BNT162C2 | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH SE | PFIZER | 19-04-2021 | Q4 2020 | NCT04368728 | - |
| 33 | APPROVED (USA, ISRAEL, EUROPE) | USA | SARS-COV2 (COVID-19) | Spikevax | MRNA-1273 | RNA VACCINE | A PROTEIN FRAGMENT | MODERNA TX, INC. | BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) | 27-10-2022 | Q4 2020 | NCT04470427 | - |
| 34 | APPROVED (USA, ISRAEL, EUROPE) | USA | SARS-COV2 (COVID-19) | Spikevax | MRNA-1273 | RNA VACCINE | A PROTEIN FRAGMENT | MODERNA TX, INC. | BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | 01-08-2021 | Q4 2020 | NCT04405076 | - |
| 35 | APPROVED (USA, ISRAEL, EUROPE) | USA | SARS-COV2 (COVID-19) | Spikevax | MRNA-1273 | RNA VACCINE | A PROTEIN FRAGMENT | MODERNA TX, INC. | BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | 30-06-2022 | Q4 2020 | NCT04649151 | - |
| 36 | APPROVED (CANADA), APPROVED FOR EMERGENCY USE (USA, BAHRAIN) | USA | SARS-COV2 (COVID-19) | JNJ-78436735 (Ad26.COV2-S) | Ad26.COV2.S | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | JOHNSONS AND JOHNSONS | 15-09-2021 | Q2 2021 | NCT04436276 | - |
| 37 | APPROVED FOR EMERGENCY USE (PHASE 3) | BRAZIL | SARS-COV2 (COVID-19) | CORONAVAC | ADSORBED COVID-19 (INACTIVATED) VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SINOVAC | 01-09-2021 | Q1 2021 | NCT04456595 | - |
| 38 | APPROVED FOR LIMITED USE (PHASE 3) | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | INSITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA OF CHINA | CANSINO BIOLOGICS INC. | JIANGSU PROVINCE CENTERS FOR DISEASE CONTROL AND PREVENTION | HUBEI PROVINCIAL CENTER FOR DISEA | 31-01-2021 | Q1 2021 | NCT04341389 | CTII-NCOV |
| 39 | APPROVED FOR EARLY USE (PHASE 3) | RUSSIA | SARS-COV2 (COVID-19) | EpiVacCorona | PEPTIDE ANTIGENS | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | VECTOR INSTITUTE | 28-09-2020 | Q4 2020 | NCT04527575 | - |
| 40 | APPROVED FOR EARLY USE (PHASE 3) | RUSSIA | SARS-COV2 (COVID-19) | CoviVac | INACTIVATED CORONAVIRUS | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | CHUMAKOV CENTER (RUSSIAN ACADEMY OF SCIENCES) | - | Q1 2021 | - | - |
| 41 | TERMINATED | BELGIUM | SARS-COV2 (COVID-19) | CoVepiT | COVEPIT (OSE13E) | DNA VACCINE | A PROTEIN FRAGMENT | OSE IMMUNOTHERAPEUTICS | 30-09-2021 | Q2 2022 | NCT04885361 | COVEPIT 3 |
| 42 | TERMINATED | AUSTRALIA | SARS-COV2 (COVID-19) | - | MOLECULAR CLAMP STABILIZED SPIKE PROTEIN WITH MF59 ADJUVANT | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | UNIVERSITY OF QUEENSLAND | CSL |SEQIRUS | NA | Q2 2021 | ACTRN12620000674932 | - |
| 43 | TERMINATED | BELGIUM | FRANCE | SARS-COV2 (COVID-19) | TMV-083 | TMV-083 | RNA VACCINE | A PROTEIN FRAGMENT | INSTITUT PASTEUR | THEMIS BIOSCIENCE GMBH | COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS | 01-11-2020 | Q1 2022 | NCT04497298 | - |
| 44 | TERMINATED | GERMANY | SARS-COV2 (COVID-19) | CVnCoV | CVnCoV | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CUREVAC AG | 30-06-2021 | Q1 2023 | NCT04674189 | - |
| 45 | TERMINATED | IRAN | SARS-COV2 (COVID-19) | FAKHRAVAC | INACTIVATED SARS-COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | IRAN'S MINISTRY OF DEFENCE | - | Q2 2022 | IRCT20210206050259N1 | - |
| 46 | TERMINATED | ISRAEL | SARS-COV2 (COVID-19) | BRILIFE | VESICULAR STOMATITIS VIRUSES | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 01-11-2021 | Q2 2022 | NA | - |
| 47 | TERMINATED | UNITED KINGDOM | SARS-COV2 (COVID-19) | COVAC1 | LNP-NCOVSARNA | RNA VACCINE | A PROTEIN FRAGMENT | IMPERIAL COLLEGE LONDON | 31-07-2021 | Q1 2022 | ISRCTN17072692 ; 2020-001646-20 | COVAC1 |
| 48 | TERMINATED | USA | SARS-COV2 (COVID-19) | V590 | V590 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | MERCK SHARP & DOHME CORP. | 03-12-2021 | Q1 2022 | NCT04569786 | V590-001 |
| 49 | TERMINATED | USA | SARS-COV2 (COVID-19) | AdCOVID | AD5 ADENOVIRUS | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ALTIMMUNE, INC. | 01-02-2022 | Q4 2022 | NCT04679909 | - |
| 50 | TERMINATED | USA | SARS-COV2 (COVID-19) | INO-4800 | INO-4800 | DNA VACCINE | A PROTEIN FRAGMENT | INOVIO PHARMACEUTICALS | 02-09-2022 | Q2 2023 | NCT04642638 | - |
| 51 | PHASE 4 | BRAZIL | SARS-COV2 (COVID-19) | - | BCG VACCINE | REPURPOSED VACCINES | MULTIDISEASE/MULTIPATHOGEN VECTOR VACCINE | UNIVERSITY OF CAMPINAS, BRAZIL | 01-06-2021 | Q4 2021 | NCT04369794 | - |
| 52 | PHASE 4 | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED MYCOBACTERIUM VACCINE | REPURPOSED VACCINES | MULTIDISEASE/MULTIPATHOGEN VECTOR VACCINE | GUANGXI MEDICAL UNIVERSITY | 12-12-2022 | Q2 2023 | ChiCTR2000030016 | - |
| 53 | PHASE 4 | GREECE | SARS-COV2 (COVID-19) | - | BCG VACCINE | REPURPOSED VACCINES | MULTIDISEASE/MULTIPATHOGEN VECTOR VACCINE | HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | 25-05-2021 | Q4 2021 | NCT04414267 | ACTIVATE II |
| 54 | PHASE 4 | USA | SARS-COV2 (COVID-19) | - | VACCINATED WITH POLIO VACCINE (IPV) | REPURPOSED VACCINES | MULTIDISEASE/MULTIPATHOGEN VECTOR VACCINE | E-MO BIOLOGY INC | 15-01-2021 | Q4 2021 | NCT04639375 | - |
| 55 | PHASE 3 | UAE | SARS-COV2 (COVID-19) | GAM-COVID-VAC | GAM-COVID-VAC | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY | HEALTH MINISTRY OF THE RUSSIAN FEDERATION|PDC-CRO | 01-08-2021 | Q2 2022 | NCT04656613 | SPUTNIK-UAE |
| 56 | PHASE 3 | CANADA | SARS-COV2 (COVID-19) | VPM1002 | VPM1002 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY HEALTH NETWORK, TORONTO | SERUM INSTITUTE OF INDIA PVT. LTD. | MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY | VERITY PHARMACEUTICALS | BILL GATES FOUNDATION | 01-06-2021 | Q1 2022 | NCT04439045 | COBRA |
| 57 | PHASE 3 | CANADA | SARS-COV2 (COVID-19) | - | CORONAVIRUS-LIKE PARTICLE COVID-19 VACCINE (PLANT DERIVED VLP) | RNA VACCINE | A PROTEIN FRAGMENT | MEDICAGO;'GSK;'DYNAVAX | 30-04-2021 | Q4 2021 | NCT04450004 | - |
| 58 | PHASE 3 | AUSTRALIA | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | MURDOCH CHILDRENS RESEARCH INSTITUTE | ROYAL CHILDREN'S HOSPITAL | 30-06-2021 | Q4 2021 | NCT04327206 | BRACE |
| 59 | PHASE 3 | BAHRAIN | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE (VERO CELL) | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CHINA NATIONAL BIOTEC GROUP COMPANY LIMITED | G42 HEALTHCARE COMPANY|ABU DHABI HEALTH SERVICES COMPANY | WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD | BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS CO., | 16-03-2021 | Q4 2021 | NCT04510207 | COVID-19 |
| 60 | PHASE 3 | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT NEW CORONAVIRUS VACCINE (Sf9 CELL) | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY | 16-11-2021 | Q1 2022 | ChiCTR2000039994 | - |
| 61 | PHASE 3 | CHINA | SARS-COV2 (COVID-19) | Ad5-nCoV | RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) | RNA VACCINE | A PROTEIN FRAGMENT | CANSINO BIOLOGICS INC. | INSTITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES. PLA OF CHINA | JIANGSU PROVINCE CENTERS FOR DISEASE CONTROL AND PREVENTION | HUBEI PROVINCIAL CENTER FOR DISE | 30-12-2020 | Q2 2021 | NCT04313127 | CTCOVID-19 |
| 62 | PHASE 3 | CHINA | SARS-COV2 (COVID-19) | - | CORONAVIRUS SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | UNIVERSITY OF HONG KONG AND XIAMEN UNIVERSITY | - | Q2 2022 | - | - |
| 63 | PHASE 3 | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT SARS-COV-2 VACCINE (CHO CELL) | RNA VACCINE | A PROTEIN FRAGMENT | LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD | NATIONAL VACCINE AND SERUM INSTITUTE, CHINA | 25-10-2022 | Q2 2023 | NCT04869592 | - |
| 64 | PHASE 3 | CHINA | SARS-COV2 (COVID-19) | SCTV01C | SCTV01E | mRNA vaccine | RNA VACCINE | A PROTEIN FRAGMENT | SINOCELLTECH | - | Q3 2022 | - | - |
| 65 | PHASE 3 | COLOMBIA | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | UNIVERSITY OF ANTIOQUIA | 01-06-2021 | Q4 2021 | NCT04362124 | - |
| 66 | PHASE 3 | DENMARK | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | BANDIM HEALTH PROJECT | UNIVERSITY OF SOUTHERN DENMARK | 01-01-2021 | Q3 2021 | NCT04373291 | - |
| 67 | PHASE 3 | EGYPT | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | AIN SHAMS UNIVERSITY | 01-10-2020 | Q2 2021 | NCT04350931 | - |
| 68 | PHASE 3 | EGYPT | SARS-COV2 (COVID-19) | - | MEASLES-MUMPS-RUBELLA VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | KASR EL AINI HOSPITAL | 01-10-2020 | Q2 2021 | NCT04357028 | - |
| 69 | PHASE 3 | FRANCE | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | ASSISTANCE PUBLIQUE - H'PITAUX DE PARIS | 11-02-2021 | Q4 2021 | NCT04384549 | - |
| 70 | PHASE 3 | GERMANY | SARS-COV2 (COVID-19) | VPM1002 | VPM1002 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | VAKZINE PROJEKT MANAGEMENT GMBH | FGK CLINICAL RESEARCH GMBH | 31-05-2021 | Q1 2022 | NCT04435379 | - |
| 71 | PHASE 3 | GERMANY | SARS-COV2 (COVID-19) | VPM1002 | VPM1002 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | VAKZINE PROJEKT MANAGEMENT GMBH | FGK CLINICAL RESEARCH GMBH | 30-06-2021 | Q1 2022 | NCT04387409 | - |
| 72 | PHASE 3 | GERMANY | SARS-COV2 (COVID-19) | CVnCoV | CVnCoV | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CUREVAC | 01-11-2021 | Q2 2021 | NCT04515147 | - |
| 73 | PHASE 3 | JAPAN | SARS-COV2 (COVID-19) | S-268019 | S-268019 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | SHIONOGI | NATIONAL INSTITUTE OF INFECTIOUS DISEASES | KYUSHU UNIVERSITY | 05-01-2022 | Q2 2022 | jRCT2051210151 | - |
| 74 | PHASE 3 | INDIA | SARS-COV2 (COVID-19) | HGC019 | mRNA VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | GENNOVA BIOPHARMACEUTICALS | HDT BIO | NA | Q4 2021 | NA | - |
| 75 | PHASE 3 | IRAN | SARS-COV2 (COVID-19) | - | RAZI COV PARS | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | RAZI VACCINE & SERUM RESEARCH INSTITUTE | - | Q4 2021 | 52975 | - |
| 76 | PHASE 3 | IRAN | SARS-COV2 (COVID-19) | NOORA | PROTEIN-BASED VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES | - | Q4 2022 | - | - |
| 77 | PHASE 3 | MEXICO | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | HOSPITAL UNIVERSITARIO DR. JOSE E. GONZALEZ | 01-01-2021 | Q4 2021 | NCT04461379 | - |
| 78 | PHASE 3 | POLAND | SARS-COV2 (COVID-19) | BCG-10 VACCINE | BCG-10 VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | HANNA CZAJKA|MEDICAL RESEARCH AGENCY - AGENCJA BADA' | MEDYCZNYCH|UNIVERSITY OF RZESZOW | 01-12-2020 | Q2 2021 | NCT04648800 | - |
| 79 | PHASE 3 | RUSSIA | SARS-COV2 (COVID-19) | - | ADENOVIRUS TYPE 5 VECTOR | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | NPO PETROVAX | CANSINO BIOLOGICS INC. | 30-11-2020 | Q2 2021 | NCT04540419 | - |
| 80 | PHASE 3 | SOUTH AFRICA | SARS-COV2 (COVID-19) | - | BCG VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | TASK APPLIED SCIENCE | 28-04-2021 | Q4 2021 | NCT04379336 | - |
| 81 | PHASE 3 | SPAIN | SARS-COV2 (COVID-19) | RUTI | RUTIA VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | PERE-JOAN CARDONA | FUNDACIó INSTITUT GERMANS TRIAS I PUJOL | 20-12-2020 | Q3 2021 | NCT04453488 | - |
| 82 | PHASE 3 | TURKEY | SARS-COV2 (COVID-19) | ERUCOV-VAC | INACTIVE VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | ERCIYES UNIVERSITY | KOCAK PHARMA | NA | Q1 2022 | NA | - |
| 83 | PHASE 3 | UNITED KINGDOM | SARS-COV2 (COVID-19) | - | SARS-COV-2 RS | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | NOVAVAX | 01-01-2021 | Q4 2021 | NCT04583995 | - |
| 84 | PHASE 3 | UNITED KINGDOM | FRANCE | SARS-COV2 (COVID-19) | - | RECOMBINANT PROTEIN-BASED VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | SANOFI | GSK | 01-11-2020 | Q2 2021 | NCT04537208 | - |
| 85 | PHASE 3 | USA | SARS-COV2 (COVID-19) | - | ORAL POLIO VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | NEUROACTIVA, INC.|BIOMED INDUSTRIES, INC. | 01-11-2022 | Q2 2023 | NCT04540185 | OPV-NA831 |
| 86 | PHASE 3 | USA | SARS-COV2 (COVID-19) | NVX-CoV2373 | RECOMBINANT SARS COV-2 GLYCOPROTEIN | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | NOVAVAX | 01-12-2020 | Q1 2021 | NCT04368988 | - |
| 87 | PHASE 3 | VIETNAM | SARS-COV2 (COVID-19) | - | NA | NA | NA | NANOGEN | NA | NA | NA | - |
| 88 | PHASE 2| PHASE 3 | AUSTRALIA | SARS-COV2 (COVID-19) | SCB-2019 | SCB-2019 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CLOVER BIOPHARMACEUTICALS AUS PTY LTD | GLAXOSMITHKLINE | 'SANOFI | 20-10-2020 | Q4 2021 | NCT04405908 | - |
| 89 | PHASE 2| PHASE 3 | CHINA | SARS-COV2 (COVID-19) | ReCOV | RECOMBINANT TWO-COMPONENT COVID-19 VACCINE (CHO CELL) | RNA VACCINE | A PROTEIN FRAGMENT | JIANGSU REC-BIOTECHNOLOGY CO., LTD. | 01-07-2021 | Q4 2022 | NCT04818801 | - |
| 90 | PHASE 2| PHASE 3 | GERMANY | SARS-COV2 (COVID-19) | GRAD-COV2 | GORILLA-DERIVED REPLICATION-DEFECTIVE ADENOVIRAL VECTOR | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | REITHERA | LEUKOCARE | 01-12-2021 | Q1 2021 | NA | - |
| 91 | PHASE 2| PHASE 3 | JAPAN | SARS-COV2 (COVID-19) | S-268019 | RECOMBINANT PROTEIN VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | SHIONOGI | NA | Q4 2021 | NA | - |
| 92 | PHASE 2| PHASE 3 | JAPAN | SARS-COV2 (COVID-19) | KD-414 | KD-414 | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | KM BIOLOGICS | NA | Q2 2023 | jRCT2071210081 | - |
| 93 | PHASE 2| PHASE 3 | JAPAN | SARS-COV2 (COVID-19) | DS-5670a | DS-5670a | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | DAIICHI SANKYO | NA | Q1 2022 | jRCT2071210106 | - |
| 94 | PHASE 2| PHASE 3 | KOREA | SARS-COV2 (COVID-19) | GX-19 | DNA VACCINE (GX-19) | RNA VACCINE | A PROTEIN FRAGMENT | GENEXINE CONSORTIUM | 17-03-2021 | Q1 2021 | NCT04445389 | - |
| 95 | PHASE 2| PHASE 3 | INDIA | SARS-COV2 (COVID-19) | GAM-COVID-VAC | GAM-COVID-VAC | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | DR. REDDY'S LABORATORIES LIMITED | GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY | HEALTH MINISTRY OF THE RUSSIAN FEDERATION | CRO: JSS MEDICAL RESEARCH INDIA PVT. LTD. | 01-08-2021 | Q2 2022 | NCT04640233 | - |
| 96 | PHASE 2| PHASE 3 | INDIA | SARS-COV2 (COVID-19) | BBV154 | ADENOVIRUS VECTORED COVID-19 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | BHARAT BIOTECH INTERNATIONAL LIMITED |WASHINGTON UNIVERSITY | 01-05-2021 | Q2 2022 | NCT04751682 | - |
| 97 | PHASE 2| PHASE 3 | SPAIN | SARS-COV2 (COVID-19) | HIPRA 10, HIPRA 20, HIPRA 40 | RECOMBINANT PROTEIN VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | HIPRA | 01-11-2021 | Q2 2022 | NCT05007509 | - |
| 98 | PHASE 2| PHASE 3 | USA | SARS-COV2 (COVID-19) | UB-612 | UB-612 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | COVAXX|DIAGNóSTICOS DA AMERICA | 22-03-2023 | Q4 2023 | NCT04683224 | - |
| 99 | PHASE 2| PHASE 3 | USA | SARS-COV2 (COVID-19) | AKS-452 | CORONAVIRUS SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | AKSTON BIOSCIENCES | - | - | - | - |
| 100 | PHASE 2 | AZERBAIJAN | SARS-COV2 (COVID-19) | AZD1222 | AZD1222 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | R-PHARM | ASTRAZENECA | 09-04-2021 | Q1 2022 | NCT04686773 | - |
| 101 | PHASE 2 | CANADA | SARS-COV2 (COVID-19) | PTX-COVID19-B | mRNA vaccine | RNA VACCINE | A PROTEIN FRAGMENT | PROVIDENCE THERAPEUTICS | 01-12-2021 | Q2 2022 | - | - |
| 102 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | WEST CHINA SECOND UNIVERSITY HOSPITAL | YUNNAN CENTER FOR DISEASE CONTROL AND PREVENTION | CHINESE ACADEMY OF MEDICAL SCIENCES | 01-09-2020 | Q2 2021 | NCT04412538 | - |
| 103 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | 2019-nCOV | RECOMBINANT NOVEL CORONAVIRUS (2019-NCOV) VACCINE | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CANSINO BIOLOGICAL INC. | BEIJING INSTITUTE OF BIOTECHNOLOGY | 31-01-2021 | Q3 2021 | CHICTR2000031781 | - |
| 104 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT COVID-19 VACCINE (SF9 CELLS) | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | JIANGSU PROVINCE CENTERS FOR DISEASE CONTROL AND PREVENTION | WEST CHINA HOSPITAL | 18-02-2021 | Q4 2021 | NCT04640402 | - |
| 105 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | - | ADENOVIRUS TYPE 5 VECTOR | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CANSINO BIOLOGICS INC.|BEIJING INSTITUTE OF BIOTECHNOLOGY|JIANGSU PROVINCE CENTERS FOR DISEASE CONTROL AND PREVENTION | 21-08-2021 | Q3 2022 | NCT04566770 | - |
| 106 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | BNT162B2 | BNT162B2 | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH SE | SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO, LTD. | 01-12-2021 | Q3 2022 | NCT04649021 | - |
| 107 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | - | SARS-COV-2 VACCINE (CHO CELL) | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ZHONGYIANKE BIOTECH | 07-04-2021 | Q3 2022 | NCT04636333 | - |
| 108 | PHASE 2 | CHINA | SARS-COV2 (COVID-19) | 202-CoV | SPIKE PROTEIN VACCINE (CHO CELL) | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | SHANGHAI ZERUN BIOTECHNOLOGY CO.,LTD | WALVAX BIOTECHNOLOGY CO., LTD. | 01-12-2021 | Q2 2022 | NCT04982068 | - |
| 109 | PHASE 2 | GERMANY | SARS-COV2 (COVID-19) | - | MULTIPEPTIDE COCKTAIL | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | UNIVERSITY OF TU'BINGEN | 30-09-2021 | Q2 2022 | NCT04546841 | - |
| 110 | PHASE 2 | NETHERLANDS | SARS-COV2 (COVID-19) | PREVENT-nCoV | ABNCOV2 VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | BAVARIAN NORDIC | - | Q1 2023 | NA | - |
| 111 | PHASE 2 | RUSSIA | SARS-COV2 (COVID-19) | GAM-COVID-VAC | GAM-COVID-VAC | RNA VACCINE | A PROTEIN FRAGMENT | GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY | HEALTH MINISTRY OF THE RUSSIAN FEDERATION | 30-12-2020 | Q2 2021 | NCT04587219 | - |
| 112 | PHASE 2 | SINGAPORE | SARS-COV2 (COVID-19) | LUNAR-COV19 | LUNAR-COV19 | RNA VACCINE | A PROTEIN FRAGMENT | ARCTURUS THERAPEUTICS AND DUKENUS | 01-12-2020 | Q3 2021 | NCT04480957 | - |
| 113 | PHASE 2 | SOUTH AFRICA | SARS-COV2 (COVID-19) | SARS-COV-2 RS | SARS-COV-2 RS | RNA VACCINE | A PROTEIN FRAGMENT | NOVAVAX | BILL AND MELINDA GATES FOUNDATION | 01-11-2021 | Q3 2022 | NCT04533399 | - |
| 114 | PHASE 2 | TAIWAN | SARS-COV2 (COVID-19) | UB-612 | UB-612 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | COVAXX | UNITED BIOMEDICAL INC., ASIA | 31-12-2020 | Q1 2021 | NCT04545749 | - |
| 115 | PHASE 2 | THAILAND | SARS-COV2 (COVID-19) | - | NDV-HXP-S VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | MAHIDOL UNIVERSITY | 01-04-2022 | Q4 2022 | NCT04764422 | - |
| 116 | PHASE 2 | THAILAND | SARS-COV2 (COVID-19) | ChulaCov19 | RNA-BASED VACCINE MRNA | RNA VACCINE | A PROTEIN FRAGMENT | CHULA VACCINE RESEARCH CENTER | CHULALONGKORN UNIVERSITY | 01-03-2021 | Q3 2021 | NCT04566276 | - |
| 117 | PHASE 2 | TURKEY | SARS-COV2 (COVID-19) | - | SARS-COV-2 VLP VACCINE | INACTIVATED VIRUS | A PROTEIN FRAGMENT | SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY | MIDDLE EAST TECHNICAL UNIVERSITY | BILKENT UNIVERSITY | 01-01-2022 | Q4 2022 | NCT04818281 | - |
| 118 | PHASE 2 | UNITED KINGDOM | SARS-COV2 (COVID-19) | SNG001 | INTERFERON BETA (IFN-') | RNA VACCINE | A PROTEIN FRAGMENT | SYNAIRGEN RESEARCH LTD. | 01-02-2021 | Q2 2021 | NCT04385095 | - |
| 119 | PHASE 2 | USA | SARS-COV2 (COVID-19) | INO-4800 | INO-4800, DEVICE: CELLECTRA' 200 | RNA VACCINE | A PROTEIN FRAGMENT | INTERNATIONAL VACCINE INSTITUTE | COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS | INOVIO PHARMACEUTICALS | 22-02-2022 | Q1 2022 | NCT04447781 | - |
| 120 | PHASE 2 | USA | SARS-COV2 (COVID-19) | COH04S1 | SYNTHETIC MVA-BASED COH04S1 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | CITY OF HOPE MEDICAL CENTER | NATIONAL CANCER INSTITUTE (NCI) | 10-11-2022 | Q2 2023 | NCT04639466 | - |
| 121 | PHASE 2 | USA | SARS-COV2 (COVID-19) | VXA-CoV2-1 | VXA-CoV2-1 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | VAXART | 01-12-2020 | Q2 2021 | NCT04563702 | - |
| 122 | PHASE 2 | USA | SARS-COV2 (COVID-19) | - | hAd5-S-FUSION+N-ETSD VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | IMMUNITYBIO, INC. | 19-11-2021 | Q2 2022 | NCT04591717 | - |
| 123 | PHASE 1B|PHASE 2B | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | CHINESE ACADEMY OF MEDICAL SCIENCES | WEST CHINA SECOND UNIVERSITY HOSPITAL | YUNNAN CENTER FOR DISEASE CONTROL AND PREVENTION | 01-11-2020 | Q2 2021 | NCT04470609 | - |
| 124 | PHASE 1B|PHASE 2 | USA | SARS-COV2 (COVID-19) | AV-COVID-19 | AV-COVID-19 | RNA VACCINE | A PROTEIN FRAGMENT | AIVITA BIOMEDICAL, INC. | 01-12-2020 | Q2 2021 | NCT04386252 | - |
| 125 | PHASE 1|PHASE 2 | CANADA | SARS-COV2 (COVID-19) | COVAC | COVAC-2 | RNA VACCINE | A PROTEIN FRAGMENT | Vaccine and Infectious Disease Organization (VIDO) | 01-10-2023 | Q2 2023 | NCT04702178 | - |
| 126 | PHASE 1|PHASE 2 | CANADA | SARS-COV2 (COVID-19) | - | V-SARS | RNA VACCINE | A PROTEIN FRAGMENT | IMMUNITOR LLC | 15-05-2021 | Q4 2021 | NCT04380532 | - |
| 127 | PHASE 1|PHASE 2 | CANADA | SARS-COV2 (COVID-19) | Ad5-nCoV | RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) | RNA VACCINE | A PROTEIN FRAGMENT | CANSINO BIOLOGICS INC. | BEIJING INSTITUTE OF BIOTECHNOLOGY | CANADIAN CENTER FOR VACCINOLOGY | 30-12-2021 | Q1 2022 | NCT04398147 | - |
| 128 | PHASE 1|PHASE 2 | CANADA | SARS-COV2 (COVID-19) | VBI-2902a | ENVELOPED VIRUS-LIKE PARTICLE (EVLP) OF SARS-COV-2 SPIKE (S) GLYCOPROTEIN | INACTIVATED VIRUS | A PROTEIN FRAGMENT | VBI VACCINES INC. | 01-06-2022 | Q4 2022 | NCT04773665 | - |
| 129 | PHASE 1|PHASE 2 | CHINA | SARS-COV2 (COVID-19) | SYNTHETIC MINIGENE VACCINE | LV-SMENP-DC VACCINE AND ANTIGEN-SPECIFIC CTLS | RNA VACCINE | A PROTEIN FRAGMENT | SHENZHEN GENO-IMMUNE MEDICAL INSTITUTE | SHENZHEN THIRD PEOPLE'S HOSPITAL | SHENZHEN SECOND PEOPLE'S HOSPITAL | 31-07-2023 | Q4 2024 | NCT04276896 | - |
| 130 | PHASE 1|PHASE 2 | CHINA | SARS-COV2 (COVID-19) | - | GENETICALLY ENGINEERED SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | SINOPHARM | 30-12-2021 | Q1 2022 | - | - |
| 131 | PHASE 1|PHASE 2 | GERMANY | SARS-COV2 (COVID-19) | BNT162B3 | BNT162B3 | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH RNA PHARMACEUTICALS GMBH | BIONTECH SE | 01-09-2021 | Q3 2022 | NCT04537949 | - |
| 132 | PHASE 1|PHASE 2 | ITALY | SARS-COV2 (COVID-19) | COVID-eVax | DNA FRAGMENT | DNA VACCINE | A PROTEIN FRAGMENT | TAKIS | ROTTAPHARM BIOTECH | NA | Q4 2021 | NA | - |
| 133 | PHASE 1|PHASE 2 | ITALY | SARS-COV2 (COVID-19) | - | MRNA COVID-19 VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | SANOFI | TRANSLATE BIO | NA | Q2 2022 | NA | - |
| 134 | PHASE 1|PHASE 2 | JAPAN | SARS-COV2 (COVID-19) | DS-5670 | mRNA VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | DAIICHI SANKYO|UNIVERSITY OF TOKYO | NA | Q4 2022 | NA | - |
| 135 | PHASE 1|PHASE 2 | JAPAN | SARS-COV2 (COVID-19) | TAK-919 | TAK-919 | RNA VACCINE | A PROTEIN FRAGMENT | TAKEDA | 11-03-2022 | Q4 2022 | NCT04677660 | - |
| 136 | PHASE 1|PHASE 2 | JAPAN | SARS-COV2 (COVID-19) | AG0301-COVID19 | AG0301-COVID19 | RNA VACCINE | A PROTEIN FRAGMENT | OSAKA UNIVERSITY | ANGES | TAKARA BIO | 26-09-2020 | Q2 2021 | NCT04463472, JapicCTI-205328 | - |
| 137 | PHASE 1|PHASE 2 | JAPAN | SARS-COV2 (COVID-19) | KD-414 | RECOMBINANT PROTEIN VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | KM BIOLOGICS CO | NA | NA | NA | - |
| 138 | PHASE 1|PHASE 2 | JAPAN | SARS-COV2 (COVID-19) | EXG-5003 | COVID-19 SELF-REPLICATING MRNA VACCINE INTRADERMAL | RNA VACCINE | A PROTEIN FRAGMENT | FUJITA HEALTH UNIVERSITY | ELIXIRGEN THERAPEUTICS, INC. | 31-01-2023 | Q4 2023 | NCT04863131 | - |
| 139 | PHASE 1|PHASE 2 | KAZAKHSTAN | SARS-COV2 (COVID-19) | QazCoVac-P | INACTIVATED CORONAVIRUSES | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS | 01-12-2021 | Q4 2022 | NCT04930003 | - |
| 140 | PHASE 1|PHASE 2 | NORWAY | SARS-COV2 (COVID-19) | VB10.2129/ VB10.2210 | VB10.2129/ VB10.2210 | DNA VACCINE | A PROTEIN FRAGMENT | NYKODE THERAPEUTICS | 01-06-2022 | Q4 2022 | NCT05069623 | - |
| 141 | PHASE 1|PHASE 2 | RUSSIA | SARS-COV2 (COVID-19) | BCD-250 | ADENOVIRUS-ASSOCIATED VIRUS | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | BIOCAD | 01-08-2022 | Q4 2022 | NCT05037188 | - |
| 142 | PHASE 1|PHASE 2 | RUSSIA | SARS-COV2 (COVID-19) | BETUVAX-COV-2 | RECOMBINANT VACCINE | RECOMBINANT VACCINE | VECTOR VIRUS | HUMAN STEM CELLS INSTITUTE | - | Q4 2022 | - | - |
| 143 | PHASE 1|PHASE 2 | SOUTH AFRICA | SARS-COV2 (COVID-19) | AZD1222 | CHADOX1 NCOV-19 | RNA VACCINE | A PROTEIN FRAGMENT | UNIVERSITY OF WITWATERSRAND, SOUTH AFRICA | MEDICAL RESEARCH COUNCIL, SOUTH AFRICA | BILL AND MELINDA GATES FOUNDATION | UNIVERSITY OF OXFORD | 01-10-2020 | Q4 2020 | NCT04444674 | - |
| 144 | PHASE 1|PHASE 2 | SOUTH AFRICA | SARS-COV2 (COVID-19) | AAHI-SC2 | sARNA COVID-19 BOOST VACCINES | RNA VACCINE | A PROTEIN FRAGMENT | IMMUNITYBIO, INC | 01-06-2023 | Q2 2024 | NCT05370040 | - |
| 145 | PHASE 1|PHASE 2 | SOUTH KOREA | SARS-COV2 (COVID-19) | AdCLD-CoV19 | AdCLD-CoV19 | RNA VACCINE | A PROTEIN FRAGMENT | CELLID | 01-04-2021 | Q4 2021 | NCT04666012 | - |
| 146 | PHASE 1|PHASE 2 | SOUTH KOREA | SARS-COV2 (COVID-19) | GBP510 | GBP510 | RNA VACCINE | A PROTEIN FRAGMENT | SK BIOSCIENCE | 01-08-2021 | Q4 2021 | NCT04742738 | - |
| 147 | PHASE 1|PHASE 2 | SOUTH KOREA | SARS-COV2 (COVID-19) | EuCorVac-19 | CORONAVIRUS SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | EUBIOLOGICS | 01-06-2021 | Q2 2022 | - | - |
| 148 | PHASE 1|PHASE 2 | SOUTH KOREA | SARS-COV2 (COVID-19) | EG-COVID | MRNA LIPOSOMES VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | EYEGENE | 01-12-2021 | Q2 2022 | - | - |
| 149 | PHASE 1|PHASE 2 | USA | SARS-COV2 (COVID-19) | KBP-COVID-19 | KBP-COVID-19 (RBD-based vaccine) | RNA VACCINE | A PROTEIN FRAGMENT | KENTUCKY BIOPROCESSING, INC | 25-01-2021 | Q4 2021 | NCT04473690 | - |
| 150 | PHASE 1|PHASE 2 | USA | SARS-COV2 (COVID-19) | IVX-411 | CORONAVIRUS SPIKE PROTEIN | RNA VACCINE | A PROTEIN FRAGMENT | ICOSAVAX | UNIVERSITY OF WASHINGTON | - | Q2 2022 | - | - |
| 151 | PHASE 1 | AUSTRALIA | SARS-COV2 (COVID-19) | - | HEPATITIS B SURFACE ANTIGEN (HBSAG) VIRUS LIKE PARTICLE (VLP) | RNA VACCINE | A PROTEIN FRAGMENT | SPYBIOTECH | SERUM INSTITUTE OF INDIA PVT LTD | 30-03-2021 | Q1 2022 | ACTRN12620000817943 | - |
| 152 | PHASE 1 | AUSTRALIA | SARS-COV2 (COVID-19) | COVIGEN | DNA-BASED VACCINE | DNA VACCINE | A PROTEIN FRAGMENT | BIONET CO., LTD | TECHNOVALIA | 30-06-2022 | Q4 2022 | NCT04742842 | COVALIA |
| 153 | PHASE 1 | AUSTRALIA | SARS-COV2 (COVID-19) | COVID-19-EDV | DNA-BASED VACCINE | DNA VACCINE | A PROTEIN FRAGMENT | EnGeneIC | - | Q4 2022 | - | - |
| 154 | PHASE 1 | CANADA | SARS-COV2 (COVID-19) | - | bacTRL-Spike | RNA VACCINE | A PROTEIN FRAGMENT | SYMVIVO CORPORATION | 31-08-2021 | Q2 2021 | NCT04334980 | - |
| 155 | PHASE 1 | CANADA | SARS-COV2 (COVID-19) | Covigenix VAX-001 | PLASMID DNA VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | ENTOS PHARMACEUTICALS INC. | 01-06-2021 | Q4 2021 | NCT04591184 | - |
| 156 | PHASE 1 | CANADA | SARS-COV2 (COVID-19) | Ad5-triCoV/Mac/ChAd-triCoV/Mac | Ad5-triCoV/Mac/ChAd-triCoV/Mac | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | CANADIAN INSTITUTES OF HEALTH RESEARCH (CIHR) | 30-06-2023 | Q4 2023 | NCT05094609 | - |
| 157 | PHASE 1 | CUBA | SARS-COV2 (COVID-19) | SOBERANA 1 | PROTEINS FROM A BACTERIA | RNA VACCINE | A PROTEIN FRAGMENT | FINLAY VACCINE INSTITUTE | 30-10-2020 | Q4 2021 | IFV/COR/04 | - |
| 158 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | INACTIVATED SARS-COV-2 VACCINE(VERO CELLS) | RNA VACCINE | A PROTEIN FRAGMENT | LI GUIFAN | 02-10-2020 | Q4 2021 | CHICTR2000038804 | - |
| 159 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | 2019-COV | RECOMBINANT NOVEL CORONAVIRUS (2019-COV) VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | CANSINO BIOLOGICAL INC. | BEIJING INSTITUTE OF BIOTECHNOLOGY | 01-12-2020 | Q2 2021 | CHICTR2000030906 | - |
| 160 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | BNT162B1 | BNT162B1 | RNA VACCINE | A PROTEIN FRAGMENT | JIANGSU PROVINCIAL CENTER FOR DISEASE PREVENTION AND CONTROL | 01-08-2020 | Q1 2021 | ChiCTR2000034825 | - |
| 161 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT NEW CORONAVIRUS VACCINE (CHO CELL) | RNA VACCINE | A PROTEIN FRAGMENT | ANHUI ZHIFEI LONGCOM BIOLOGIC PHARMACY CO., LTD. | THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY | BEIJING CHAO YANG HOSPITAL | 21-07-2021 | Q4 2021 | NCT04445194 | - |
| 162 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | PATHOGEN-SPECIFIC AAPC | RNA VACCINE | A PROTEIN FRAGMENT | SHENZHEN GENO-IMMUNE MEDICAL INSTITUTE | SHENZHEN THIRD PEOPLE'S HOSPITAL | SHENZHEN SECOND PEOPLE'S HOSPITAL | 31-07-2023 | Q4 2024 | NCT04299724 | - |
| 163 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | RNA-BASED VACCINE MRNA | RNA VACCINE | A PROTEIN FRAGMENT | PEOPLE'S LIBERATION ARMY (PLA) ACADEMY OF MILITARY SCIENCES | WALVAX BIOTECH | 31-12-2021 | Q2 2022 | CHICTR2000034112 | - |
| 164 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | MicroRNA2911 | RNA VACCINE | A PROTEIN FRAGMENT | IMMUNITOR LLC | 31-08-2020 | Q3 2021 | ChiCTR2000031432 | - |
| 165 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | RECOMBINANT NEW CORONAVIRUS VACCINE (CHO CELL) | RNA VACCINE | A PROTEIN FRAGMENT | ANHUI ZHIFEI LONGCOM BIOLOGIC PHARMACY CO., LTD. | 31-10-2021 | Q3 2022 | NCT04550351 | - |
| 166 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | BNT162B1 | BNT162B1 | RNA VACCINE | A PROTEIN FRAGMENT | BIONTECH RNA PHARMACEUTICALS GMBH | SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO, LTD. | BIONTECH SE | 30-09-2020 | Q1 2021 | NCT04523571 | - |
| 167 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | mRNA vaccine | RNA VACCINE | A PROTEIN FRAGMENT | STEMIRNA THERAPEUTICS | SHANGHAI EAST HOSPITA | - | Q4 2022 | ChiCTR2100045984 | - |
| 168 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | PIKA-ADJUVANTED RECOMBINANT SARS-COV-2 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | YISHENG BIOPHARMA | - | Q4 2022 | ACTRN12621001009808 | - |
| 169 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | MRNA VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | AIM VACCINE | LIVERNA THERAPEUTICS | - | Q4 2022 | ChiCTR131000 | - |
| 170 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | - | MRNA VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | CANSINO BIOLOGICS | - | Q2 2023 | - | - |
| 171 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | SYS6006 | MRNA VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | CSPC PHARMACEUTICAL GROUP | - | Q2 2023 | - | - |
| 172 | PHASE 1 | CHINA | SARS-COV2 (COVID-19) | RQ3013 | mRNA MOLECULES | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | SHANGHAI RNACURE BIOPHARMA | 31-05-2022 | Q2 2023 | - | - |
| 173 | PHASE 1 | EGYPT | SARS-COV2 (COVID-19) | - | Covi Vax | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | 23-Feb-23 | Q4 2023 | NCT05128721 | - | |
| 174 | PHASE 1 | EGYPT | SARS-COV2 (COVID-19) | EgyVax | EGYVAX | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | EVA PHARMA | 1-Oct-22 | Q4 2022 | NCT05218070 | Sphinx |
| 175 | PHASE 1 | GERMANY | SARS-COV2 (COVID-19) | CVnCoV | CVNCOV VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | CUREVAC AG | COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) | 01-08-2021 | Q2 2021 | NCT04449276 | - |
| 176 | PHASE 1 | GERMANY | SARS-COV2 (COVID-19) | MVA-SARS-2-S | MVA-SARS-2-S | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | GERMAN CENTER FOR INFECTION RESEARCH | UNIVERSIT'TSKLINIKUM HAMBURG-EPPENDORF | 01-05-2021 | Q4 2021 | NCT04569383 | - |
| 177 | PHASE 1 | INDONESIA | SARS-COV2 (COVID-19) | - | SARS-COV-2 DNA VACCINE | DNA VACCINE | A PROTEIN FRAGMENT | THE UNIVERSITY OF HONG KONG | IMMUNO CURE 3 LIMITED | 01-12-2022 | Q2 2023 | NCT05102643 | - |
| 178 | PHASE 1 | ISRAEL | SARS-COV2 (COVID-19) | MIGVAX-101 | ORAL VIRUS-LIKE PARTICLES | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ORAVAX MEDICAL | - | Q4 2022 | - | - |
| 179 | PHASE 1 | JAPAN | SARS-COV2 (COVID-19) | VLPCOV-01 | mRNA VACCINE | RNA VACCINE | A PROTEIN FRAGMENT | VLP THERAPEUTICS JAPAN | - | Q4 2022 | Jrct2071210067 | - |
| 180 | PHASE 1 | NOT STATED | SARS-COV2 (COVID-19) | COVAX-19 | COVAX-19 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | GENECURE BIOTECHNOLOGIES | 01-07-2021 | Q1 2022 | NCT04428073 | - |
| 181 | PHASE 1 | PENNSYLVANIA | SARS-COV2 (COVID-19) | CoV2-OGEN1 | ORALLY SUSPENSION OF COV2-OGEN1 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | VAXFORM | SYNEOS HEALTH | 10-12-2021 | Q2 2022 | NCT04893512 | - |
| 182 | PHASE 1 | SOUTH KOREA | SARS-COV2 (COVID-19) | GLS-5310 | GLS-5310 | DNA VACCINE | A PROTEIN FRAGMENT | GENEONE LIFE SCIENCE, INC | 31-07-2022 | Q4 2022 | NCT04673149 | - |
| 183 | PHASE 1 | SOUTH KOREA | SARS-COV2 (COVID-19) | IN-B009 | IN-B009 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | HK INNO.N CORPORATION | 01-02-2023 | Q4 2023 | NCT05113849 | - |
| 184 | PHASE 1 | SWITZERLAND | SARS-COV2 (COVID-19) | LD PepGNP-SARSCoV2 | LD PepGNP-SARSCoV2 | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | EMERGEX VACCINES | 01-10-2022 | Q1 2023 | NCT05113862 | - |
| 185 | PHASE 1 | TAIWAN | SARS-COV2 (COVID-19) | AdimrSC-2f | AdimrSC-2f | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ADIMMUNE CORPORATION | 20-11-2020 | Q4 2021 | NCT04522089 | - |
| 186 | PHASE 1 | THAILAND | SARS-COV2 (COVID-19) | Baiya SARS-CoV-2 Vax 1 | RECOMBINANT SARS-COV-2 RECEPTOR-BINDING DOMAIN FUSED WITH FC REGION OF HUMAN IGG1 VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | BAIYA PHYTOPHARM CO., LTD. | 01-12-2021 | Q4 2022 | NCT04953078 | - |
| 187 | PHASE 1 | TURKEY | SARS-COV2 (COVID-19) | KO'AK-19 | KO'AK-19 INAKTIF ADJUVANLI COVID-19 VACCINE | INACTIVATED VIRUS | A PROTEIN FRAGMENT | KOCAK FARMA | 01-06-2021 | Q2 2022 | NCT04838080 | - |
| 188 | PHASE 1 | TURKEY | SARS-COV2 (COVID-19) | - | SARS-COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY | 01-10-2021 | Q2 2022 | NCT04866069 | - |
| 189 | PHASE 1 | UNITED KINGDOM | SARS-COV2 (COVID-19) | COVI-VAC | COVI-VAC | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | CODAGENIX, INC | 01-06-2021 | Q1 2022 | NCT04619628 | - |
| 190 | PHASE 1 | UNITED KINGDOM | SARS-COV2 (COVID-19) | DIOSynVax | VIRUS SPIKE PROTEIN | DNA VACCINE | A PROTEIN FRAGMENT | UNIVERSITY OF CAMBRIDGE | - | - | - | - |
| 191 | PHASE 1 | USA | SARS-COV2 (COVID-19) | MRNA-1273 | MRNA-1273 | RNA VACCINE | A PROTEIN FRAGMENT | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) | 22-11-2021 | Q2 2021 | NCT04283461 | - |
| 192 | PHASE 1 | USA | SARS-COV2 (COVID-19) | V591 | V591 | NON REPLICATING VIRAL VECTOR | VECTOR VIRUS | MERCK SHARP & DOHME CORP. | 26-04-2022 | Q3 2022 | NCT04498247 | V591-001 |
| 193 | PHASE 1 | USA | SARS-COV2 (COVID-19) | CORVax | SPIKE (S) PROTEIN PLASMID DNA | DNA VACCINE | A PROTEIN FRAGMENT | PROVIDENCE HEALTH & SERVICES | ONCOSEC IMMUNOTHERAPIES | 01-05-2021 | Q4 2021 | NCT04627675 | - |
| 194 | PHASE 1 | USA | SARS-COV2 (COVID-19) | INO-4800 | INO-4800, DEVICE: CELLECTRA' 200 | DNA VACCINE | A PROTEIN FRAGMENT | INOVIO PHARMACEUTICALS | COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) | 01-07-2021 | Q2 2021 | NCT04336410 | - |
| 195 | PHASE 1 | USA | SARS-COV2 (COVID-19) | - | CHIMPANZEE ADENOVIRUS MRNA PRIME-BOOST PROPHYLACTIC VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | GRITSTONE ONCOLOGY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 19-09-2022 | Q2 2023 | NCT04776317 | - |
| 196 | PHASE 1 | USA | SARS-COV2 (COVID-19) | SpFN | SARS-COV-2-SPIKE-FERRITIN-NANOPARTICLE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | WALTER REED ARMY INSTITUTE OF RESEARCH | 30-10-2022 | Q2 2023 | NCT04784767 | - |
| 197 | PHASE 1 | USA | SARS-COV2 (COVID-19) | SC-Ad6-1 | GENETICALLY ENGINEERED VIRUSES | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | TETHEREX PHARMACEUTICALS CORPORATION | 30-09-2021 | Q2 2022 | NCT04839042 | - |
| 198 | PHASE 1 | USA | SARS-COV2 (COVID-19) | DoCo-Pro-RBD-1 + MF59 | ADJUVANTED SARS-COV-2 BETA VARIANT RBD RECOMBINANT PROTEIN VACCINE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | UNIVERSITY OF MELBOURNE | SOUTHERN STAR RESEARCH | 31-12-2022 | Q2 2023 | NCT05272605 | - |
| 199 | PHASE 1 | USA | SARS-COV2 (COVID-19) | CVXGA1 | INTRANASAL PIV5-SARS COV-2 VACCINE | INACTIVATED VIRUS | LIVE VIRUS (ATTENUATED) | CYANVAC LLC | 01-12-2021 | Q2 2022 | NCT04954287 | - |
| 200 | PHASE 1 | USA | SARS-COV2 (COVID-19) | ACM-001 | ACM-SARS-COV-2-BETA ACM-CPG VACCINE CANDIDATE | PROTEIN SUBUNIT | A PROTEIN FRAGMENT | ACM BIOLABS | 31-12-2022 | Q2 2023 | NCT05385991 | - |
